LINGEGOWDA SELANERE MANGALA to Angiogenesis Inhibitors
This is a "connection" page, showing publications LINGEGOWDA SELANERE MANGALA has written about Angiogenesis Inhibitors.
Connection Strength
0.414
-
Identifying and targeting angiogenesis-related microRNAs in ovarian cancer. Oncogene. 2019 08; 38(33):6095-6108.
Score: 0.098
-
Antiangiogenic and tumour inhibitory effects of downregulating tumour endothelial FABP4. Oncogene. 2017 02 16; 36(7):912-921.
Score: 0.081
-
Combined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancer. Cancer Biol Ther. 2009 Dec; 8(23):2263-72.
Score: 0.051
-
Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma. Cancer Biol Ther. 2009 Aug; 8(16):1596-603.
Score: 0.050
-
Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J Natl Cancer Inst. 2006 Nov 01; 98(21):1558-70.
Score: 0.041
-
Overcoming adaptive resistance to anti-VEGF therapy by targeting CD5L. Nat Commun. 2023 04 26; 14(1):2407.
Score: 0.032
-
Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies. J Natl Cancer Inst. 2017 07 01; 109(7).
Score: 0.021
-
Tumour angiogenesis regulation by the miR-200 family. Nat Commun. 2013; 4:2427.
Score: 0.016
-
Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models. Cancer Biol Ther. 2010 Feb; 9(3):176-82.
Score: 0.013
-
Dual targeting of EphA2 and FAK in ovarian carcinoma. Cancer Biol Ther. 2009 Jun; 8(11):1027-34.
Score: 0.012